BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

LAM Pharmaceutical Corporation (LAMP) IPM Receives First IPM Wound Gel Commercial Order For Ecuador


10/19/2005 5:12:54 PM

LEWISTON, N.Y., March 2 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it received its first commercial order for its patented and proprietary LAM IPM Wound Gel(TM) for Ecuador. The order placed by aQva Pharmaceuticals, LAM's distributor in the Central American region, was for a total of $20,000.

Mr. Salvador Ficciella, CEO of aQva Pharmaceuticals Inc. stated, "Our first order marks the beginning of a comprehensive marketing and sales campaign in Ecuador. We are very encouraged by and wish to take advantage of the overwhelmingly positive feedback from Ecuadorian doctors using LAM IPM Wound Gel(TM). Once again, we are seeing undisputable validation of the LAM IPM Wound Gel(TM) efficacy, which reaffirms our confidence in the product."

Mr. Joseph T. Slechta, President and Chief Executive Officer of LAM, noted, "As we have reported to the shareholders, our Gel is being well received throughout Central America. The commencement of commercial sales in Ecuador will not only mean a welcome addition to the Company's revenues but also marks another milestone in the successful introduction of our Gel into the Latin American market."

About LAM Pharmaceutical, Corp.

L.A.M. Pharmaceutical, Corp., http://www.lampharm.com/, is a biomedical company with offices in Lewiston, New York, Toronto, Canada and Beijing, China. L.A.M. focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 15 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.

About aQva Pharmaceuticals

aQva Pharmaceuticals is an international distribution company with headquarters in Montreal, Canada, an operating subsidiary in Mexico City and distribution partners in several Latin American Countries. aQva main business focus is to distribute pharmaceutical and healthcare products in Latin America.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.

L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.

CONTACT: Stephanie Carrington (Investors/Media) 646-536-7017 The Ruth Group

L.A.M. Pharmaceutical, Corp.

CONTACT: Investors and Media, Stephanie Carrington of The Ruth Group,+1-646-536-7017, for LAM Pharmaceutical


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->